Eli Lilly is Wednesday's IBD Stock Of The Day. Shares are breaking above a pair of bases as rumors swirl about a potential ...

UBS initiated coverage with a ‘Buy’ rating and set a $1,250 price target, citing confidence in Lilly’s obesity execution.

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than two months.

Eli Lilly (LLY 3.74%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...

Eli Lilly stock reached an all-time high of 1113.03 USD, marking a significant milestone for the pharmaceutical giant. This achievement reflects a robust 41.51% increase over the past year, ...

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be ...

Investing.com -- Ventyx Biosciences (NASDAQ:VTYX) stock surged 5% and was halted for volatility following reports that Eli Lilly (NYSE:LLY) is in advanced talks to acquire the biotech company for more ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Ventyx shares jumped in after-hours trading following reports that Eli Lilly is in advanced talks to acquire the biopharma company for over $1 billion.

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.